Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymostimulin versus placebo in advanced hepatocellular carcinoma
ISRCTN64487365Phase 3Completed
- Sponsor
- Martin-Luther-University Halle-Wittenberg (Germany)
- Start
- Oct 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Thymostimulin plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoints: 6-month survival and 12-month survival. Started Oct 2002; status: completed.
02
Drugs
thymostimulin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ISRCTN64487365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN64487365.